Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management to enhance the efficiency of fund usage while ensuring the normal operation of investment projects and the safety of the raised funds [1][5]. Group 1: Fund Management Overview - The company raised a total of RMB 897,999,976.34 through a non-public issuance of 31,420,573 shares at a price of RMB 28.58 per share, with a net amount of RMB 885,820,523.22 after deducting issuance costs [1]. - The current balance of the raised funds is RMB 201,103,541.25, with a portion remaining idle for a period [2]. Group 2: Cash Management Plan - The company intends to use up to RMB 210 million of the idle raised funds for cash management, investing in safe and liquid financial products such as structured deposits and large certificates of deposit [2][3]. - The cash management will be valid for 12 months from the approval date by the board of directors and the supervisory board [3]. Group 3: Decision-Making Process - The board of directors and the supervisory board have approved the cash management plan, which does not require shareholder meeting approval [3][5]. - The company has authorized its legal representative or designated personnel to make investment decisions within the specified limits [3]. Group 4: Impact and Benefits - The cash management is expected to improve fund utilization efficiency and enhance the overall performance of the company, providing better returns for shareholders [4][5]. - The company has established risk control measures to ensure that the cash management does not affect the normal operation of investment projects [4]. Group 5: Sponsor's Opinion - The sponsor, Huatai United Securities, has confirmed that the cash management plan complies with relevant regulations and does not harm the interests of the company or its shareholders, particularly minority shareholders [5][6].
普莱柯: 华泰联合证券有限责任公司关于普莱柯生物工程股份有限公司使用部分闲置募集资金进行现金管理的核查意见